Despoina Koulenti

List of Publications by Year
in descending order

91	7,180	109137 35	56606 83
papers	citations	h-index	g-index

99	99	99	7788
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mortality after surgery in Europe: a 7 day cohort study. Lancet, The, 2012, 380, 1059-1065.	6.3	1,614
2	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	2.9	843
3	Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. British Journal of Anaesthesia, 2016, 117, 601-609.	1.5	400
4	The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Medicine, 2015, 41, 1620-1628.	3.9	323
5	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Medicine, 2012, 38, 1930-1945.	3.9	322
6	Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1999-2006.	1.3	230
7	Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine, 2009, 37, 2360-2369.	0.4	188
8	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenzaÂA infection. Intensive Care Medicine, 2011, 37, 272-283.	3.9	188
9	Hospital mortality of adults admitted to Intensive Care Units in hospitals with and without Intermediate Care Units: a multicentre European cohort study. Critical Care, 2014, 18, 551.	2.5	154
10	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically Ill Patients*. Critical Care Medicine, 2014, 42, 601-609.	0.4	150
11	Risk factors for target non-attainment during empirical treatment with Î²-lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	3.9	147
12	Oral care practices in intensive care units: aÂsurvey of 59 European ICUs. Intensive Care Medicine, 2007, 33, 1066-1070.	3.9	134
13	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
14	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	3.9	114
15	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	2.5	108
16	Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries. Intensive Care Medicine, 2017, 43, 971-979.	3.9	108
17	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: â€œAbSeSâ€• a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	3.9	103
18	The surgical safety checklist and patient outcomes after surgery: a prospective observational cohort study, systematic review and meta-analysis. British Journal of Anaesthesia, 2018, 120, 146-155.	1.5	92

#	Article	IF	Citations
19	Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Critical Care, 2011, 15, R62.	2.5	87
20	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	2.5	87
21	Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. European Respiratory Journal, 2011, 37, 1332-1339.	3.1	78
22	Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Current Opinion in Critical Care, 2018, 24, 332-338.	1.6	78
23	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	1.1	68
24	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents, 2013, 42, 289-293.	1.1	63
25	Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270.	1.6	63
26	Approach to invasive pulmonary aspergillosis in critically ill patients. Current Opinion in Infectious Diseases, 2014, 27, 174-183.	1.3	61
27	Respiratory infections in patients undergoing mechanical ventilation. Lancet Respiratory Medicine,the, 2014, 2, 764-774.	5.2	59
28	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	1.4	59
29	Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Critical Care, 2016, 20, 53.	2.5	59
30	Cumulative Evidence of Randomized Controlled and Observational Studies on Catheter-Related Infection Risk of Central Venous Catheter Insertion Site in ICU Patients: A Pairwise and Network Meta-Analysis. Critical Care Medicine, 2017, 45, e437-e448.	0.4	59
31	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	1.1	48
32	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	1.3	47
33	Patient to Nurse Ratio and Risk of Ventilator-Associated Pneumonia in Critically Ill Patients. American Journal of Critical Care, 2011, 20, e1-e9.	0.8	43
34	The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms, 2019, 7, 159.	1.6	42
35	Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study. Intensive Care Medicine, 2018, 44, 1212-1220.	3.9	41
36	Colistin-Resistant Acinetobacter Baumannii Bacteremia: A Serious Threat for Critically Ill Patients. Microorganisms, 2020, 8, 287.	1.6	41

#	Article	IF	Citations
37	Point prevalence of surgical checklist use in Europe: relationship with hospital mortality. British Journal of Anaesthesia, 2015, 114, 801-807.	1.5	35
38	The value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studies. Critical Care, 2016, 20, 203.	2.5	35
39	Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study. Journal of the American Geriatrics Society, 2013, 61, 2065-2071.	1.3	34
40	Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Current Opinion in Critical Care, 2019, 25, 430-437.	1.6	33
41	Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. Critical Care, 2013, 17, R289.	2.5	32
42	Angiopoietin-2 associations with the underlying infection and sepsis severity. Cytokine, 2015, 73, 163-168.	1.4	29
43	COPD patients with ventilator-associated pneumonia: implications for management. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2403-2411.	1.3	29
44	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2020, 8, 191.	1.6	29
45	Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis. Infection and Drug Resistance, 2022, Volume 15, 697-721.	1.1	29
46	Quality of Life Outcome of Critical Care Survivors Eighteen Months after Discharge from Intensive Care. Croatian Medical Journal, 2007, 48, 814-821.	0.2	27
47	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy, 2006, 7, 1555-1569.	0.9	26
48	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 785-794.	1.3	25
49	Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns. International Journal of Antimicrobial Agents, 2021, 58, 106409.	1.1	24
50	Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. Antibiotics, 2022, 11, 771.	1.5	23
51	Desmoid Tumor Presenting as Intra-Abdominal Abscess. Digestive Diseases and Sciences, 2006, 51, 68-69.	1.1	22
52	Whatâ€™s new in invasive pulmonary aspergillosis in the critically ill. Intensive Care Medicine, 2014, 40, 723-726.	3.9	22
53	Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2019, 74, 667-674.	1.3	22
54	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 2014, 14, 513.	1.3	20

#	Article	IF	Citations
55	Factors associated with ventilator-associated events: an international multicenter prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1693-1699.	1.3	18
56	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. Expert Review of Anti-Infective Therapy, 2019, 17, 201-210.	2.0	17
57	Gram-negative bacterial pneumonia: aetiology and management. Current Opinion in Internal Medicine, 2006, 5, 358-364.	1.5	15
58	Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management. Microorganisms, 2021, 9, 534.	1.6	15
59	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Annals of Intensive Care, 2021, 11, 49.	2.2	15
60	World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance. Medicina Intensiva, 2015, 39, 34-39.	0.4	14
61	Lefamulin. Comment on: â€œNovel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270â€. Microorganisms, 2019, 7, 386.	1.6	14
62	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	1.1	14
63	Prospective observational cohort study on grading the severity of postoperative complications in global surgery research. British Journal of Surgery, 2019, 106, e73-e80.	0.1	13
64	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. Antibiotics, 2020, 9, 51.	1.5	13
65	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 637-647.	1.3	12
66	Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter caseâ€“control study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 123-130.	1.3	10
67	Pathogenesis-Targeted Preventive Strategies for Multidrug Resistant Ventilator-Associated Pneumonia: A Narrative Review. Microorganisms, 2020, 8, 821.	1.6	10
68	Pandrug-resistant Acinetobacter baumannii treatment: still a debatable topic with no definite solutions. Journal of Antimicrobial Chemotherapy, 2020, 75, 3081-3081.	1.3	9
69	Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 2022, 11, 892.	1.5	7
70	Persistence of colonisation with MDRO following discharge from the ICU. Intensive Care Medicine, 2014, 40, 603-605.	3.9	6
71	Nosocomial pneumonia diagnosis revisited. Current Opinion in Critical Care, 2020, 26, 442-449.	1.6	6
72	Quality of evidence supporting Surviving Sepsis Campaign Recommendations. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 497-502.	0.6	5

#	Article	IF	Citations
73	Editorial for Special Issue â€œMultidrug-Resistant Pathogensâ€• Microorganisms, 2020, 8, 1383.	1.6	5
74	Candida burn wound sepsis: The â€œholy trinityâ€•of management. Intensive and Critical Care Nursing, 2018, 46, 4-5.	1.4	4
75	Evaluation of the quality of evidence supporting guideline recommendations for the nutritional management of critically ill adults. Clinical Nutrition ESPEN, 2020, 39, 144-149.	0.5	4
76	How to measure microaspiration of subglottic secretions in clinical research in intubated patients?. Intensive and Critical Care Nursing, 2021, 63, 103010.	1.4	4
77	Update in Hospital-acquired Bacteremia Respiratory Infections. Clinical Pulmonary Medicine, 2014, 21, 9-15.	0.3	3
78	The CVC and CRBSI: donâ€™t use it and lose it!. Intensive Care Medicine, 2018, 44, 238-240.	3.9	3
79	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	2.9	2
80	Optimizing educational initiatives to prevent ventilator-associated complications. American Journal of Infection Control, 2017, 45, 102-103.	1.1	2
81	Evaluating rates of ventilator-associated pneumonia: Consider patient, organizational & educational risk factors. Indian Journal of Medical Research, 2017, 145, 697-698.	0.4	2
82	The authors reply. Critical Care Medicine, 2014, 42, e314-e315.	0.4	1
83	Patterns in the epidemiology of candidemia as a consequence of antibiotic and antifungal exposure. Burns, 2020, 46, 500-501.	1.1	1
84	Hospital-Acquired Pneumonia Caused byStaphylococcus aureus. , 0, , 107-129.		0
85	What We Learned From the EU-VAP/CAP Study for Severe Pneumonia. Clinical Pulmonary Medicine, 2017, 24, 112-120.	0.3	0
86	The authors reply. Critical Care Medicine, 2017, 45, e735-e736.	0.4	0
87	Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 59-66.	0.0	0
88	Sepsis in Obstetrics. , 2007, , 488-493.		0
89	107. Critical Care Medicine, 2012, 40, 1-328.	0.4	0
90	491. Critical Care Medicine, 2012, 40, 1-328.	0.4	0

#	Article	IF	Citations
91	Factors Influencing Outcomes in Intensive Care Unit Patients with Nosocomial Infections. Archives of Iranian Medicine, 2016, 19, 677-8.	0.2	0